● Recruiting

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Condition: Multiple Myeloma, Refractory · Sponsor: Karyopharm Therapeutics Inc

PhasePhase 2

Planned participants127

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.

This description comes directly from the study's public registry record.

Talk to the study team

Karyopharm Medical Information · (888) 209-9326 · clinicaltrials@karyopharm.com

Always discuss trial participation with your own doctor first.

Locations (16)

University General Hospital of Patras	Pátrai, Achaia, Greece	Completed
General Hospital of Athens "Alexandra"	Attiki, Athens, Greece	Recruiting
General Hospital of Athens "Evangelismos"	Athens, Attica, Greece	Recruiting
Theageneion Cancer Hospital	Thessaloniki, Thessaloniki, Greece	Recruiting
Emek Medical Center	Afula, Afula, Israel	Recruiting
Assuta Ashdod Medical Center	Ashdod, Ashdod, Israel	Recruiting
Bnai-Zion Medical Center	Haifa, Haifa District, Israel	Recruiting
Rambam Health Care Campus	Haifa, Haifa District, Israel	Recruiting
Shaare Zedek Medical Center	Jerusalem, Jerusalem, Israel	Recruiting
Hadassah Medical Center	Jerusalem, Jerusalem, Israel	Recruiting
Rabin Medical Center (Beilinson Hospital)	Petah Tikva, Petah Tikva, Israel	Recruiting
The Chaim Sheba Medical Center at Tel HaShomer	Ramat Gan, Ramat Gan, Israel	Recruiting

+ 4 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04414475